博奥生物品牌怎么样 申请店铺

我要投票 博奥生物在基因检测行业中的票数:552 更新时间:2026-01-07
博奥生物是哪个国家的品牌?「博奥生物」是 博奥生物集团有限公司 旗下著名品牌。该品牌发源于北京市,由创始人程总在2000年期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力博奥生物品牌出海!将品牌入驻外推网,定制博奥生物品牌推广信息,可以显著提高博奥生物产品曝光,简直是跨境电商爆单神器!目前仅需1000元/年哦~

博奥生物怎么样

成立于2000年,清华控股旗下,生命科学研究和健康产业的企业,打造集健康产品/健康管理和医疗康复于一体的大健康产业版块。

博奥生物集团有限公司于2000年9月30日在国务院、发改委、科技部、教育部、卫生部和北京市领导大力支持下,以清华大学为依托、联合华中科技大学、中国医学科学院、军事医学科学院注册成立,是生命科学研究和健康产业的国有创新型高科技企业。公司总部位于北京,现有员工2000多人,研发、生产、运营和服务基地超过10万平方米。

公司以生物芯片为核心技术平台,拥有研发、生产、销售以及全国第三方独立医学检验所服务为一体的大医学完整产业链,并响应国家关于“预防为主”的健康方针,将现代医学与中国传统医学紧密结合,打造出集健康产品、健康管理和医疗康复于一体的大健康产业版块。迄今,博奥生物在国内已经形成了北京、上海、重庆、成都等大型产业化基地,并形成了以北京博奥晶典生物技术有限公司为核心的产业化平台。

成立18年来,博奥生物依托清华大学和生物芯片北京国家工程研究中心雄厚的研发实力,已成功开发出生物芯片及相关试剂耗材、仪器设备、软件数据库、生命科学服务、临床检验服务、健康管理等系列数十项具有自主知识产权的产品和服务。公司先后获得德国TÜV莱茵公司颁发的ISO9001、ISO13485、ISO14000、ISO18000、ISO27000质量管理体系认证证书、美国组织相容性及遗传学协会(ASHI)认证证书和中国合格评定国家认可委员会实验室认证证书,其产品获得CFDA、CE 、GS、CB等国内外各类认证证书100余项。至今,博奥生物已在全球获得专利授权300余项,专利转化率较高。

因其优良的研发、生产、营销和服务团队,以及生物芯片技术平台和高标准的质保体系,博奥生物除与国内近百家三甲医院、高校、公安和司法机构建立了战略合作,还与罗氏应用科学、罗氏诊断、昂飞、热电等国际生命科学和医学诊断领域的公司建立了伙伴关系,产品及服务出口北美、欧洲、亚洲等三十多个国家和地区。其中,诊断用生物芯片及相关仪器产品已进入英国、德国、瑞典、意大利、西班牙、奥地利、瑞士、葡萄牙、芬兰、丹麦、日本、新加坡等国家的数百家医院。

Founded in 2000, Tsinghua holdings, a life science research and health industry enterprise, has created a large health industry section integrating health products / health management and medical rehabilitation. On September 30, 2000, with the support of the State Council, the national development and Reform Commission, the Ministry of science and technology, the Ministry of education, the Ministry of health and the leaders of Beijing Municipality, Bo'ao biological Group Co., Ltd. was established on the basis of Tsinghua University and registered with Huazhong University of science and technology, the Chinese Academy of Medical Sciences and the Academy of Military Medical Sciences. It is a state-owned innovative high-tech enterprise in life science research and health industry. The company is headquartered in Beijing, with more than 2000 employees and over 100000 square meters of R & D, production, operation and service bases. With biochip as the core technology platform, the company has a complete industrial chain of large-scale medicine integrating R & D, production, sales and the services of the national third-party independent medical laboratory. In response to the national health policy of "prevention first", the company closely combines modern medicine with traditional Chinese medicine to create a large-scale health industry integrating health products, health management and medical rehabilitation Industry forum. So far, Boao biology has formed large-scale industrialization bases in China, such as Beijing, Shanghai, Chongqing, Chengdu, and formed an industrialization platform with Beijing Boao Jingdian Biotechnology Co., Ltd. as the core. Since its establishment 18 years ago, relying on the strong R & D strength of Tsinghua University and biochip Beijing National Engineering Research Center, BOCOG bio has successfully developed dozens of products and services with independent intellectual property rights, including biochip and related reagent consumables, instruments and equipment, software database, life science services, clinical testing services, health management, etc. The company has successively obtained ISO9001, ISO13485, ISO14000, ISO18000, ISO27000 quality management system certification issued by Germany t Ü V Rhine company, Ashi certification and laboratory certification issued by China National Accreditation for conformity assessment. Its products have obtained more than 100 kinds of certification certificates at home and abroad, such as CFDA, CE, GS, CB, etc. So far, Bo'ao biology has obtained more than 300 patent authorizations in the world, with a high patent conversion rate. Due to its excellent R & D, production, marketing and service team, as well as the biochip technology platform and high standard quality assurance system, Boao biology has established strategic cooperation with nearly 100 top three hospitals, universities, public security and judicial institutions in China, as well as partnerships with companies in international life science and medical diagnosis fields such as Roche Applied Science, Roche diagnosis, onfe, thermoelectricity, etc Products and services are exported to more than 30 countries and regions in North America, Europe and Asia. Among them, diagnostic biochip and related instrument products have entered hundreds of hospitals in Britain, Germany, Sweden, Italy, Spain, Austria, Switzerland, Portugal, Finland, Denmark, Japan, Singapore and other countries.

本文链接: https://brand.waitui.com/126365a18.html 联系电话:请联系客服添加 联系邮箱:请联系客服添加

外推网广告位招租,每天只要9块9

7×24h 快讯

2025年12月份全球制造业采购经理指数较上月微幅下降

今天(7日),中国物流与采购联合会发布2025年12月份全球制造业采购经理指数,指数较上月微幅下降,全球经济基本平稳。2025年12月份全球制造业采购经理指数为49.5%,较上月微幅下降0.1个百分点,连续10个月运行在49%~50%的区间内。综合指数变化,12月全球制造业维持弱势复苏格局,但复苏强度尚未形成有效支撑,仍需进一步巩固提升。(央视新闻)

28分钟前

又有茅台经销商跟进,促销1499元/瓶飞天茅台

“1月10日,抢1499元飞天茅台。”苏州鲁智深网络科技有限公司负责人近日在其官方视频号中表示。“此次直播,就是想跟随茅台酒厂的脚步,推动真正的全面市场化,直接面对消费者。”该负责人称,当前市场上有关“茅台价格已跌破1499元/瓶”的说法并不准确。“业内普遍知道,目前飞天茅台的批发调货价仍在1500元/瓶以上。”(上证报)

28分钟前

环球音乐与英伟达宣布开展AI音乐创作与研究合作

当地时间1月6日,据报道,环球音乐集团与英伟达公司达成合作,将共同开展人工智能音乐创作与研究合作。环球音乐表示,双方将专注于利用AI技术优化乐迷的音乐发现方式和艺人互动体验。(界面)

28分钟前

算力巨头超聚变启动上市辅导

据证监会官网显示,超聚变数字技术股份有限公司于2026年1月6日正式启动上市辅导,中信证券担任辅导机构。公开资料显示,超聚变的前身是华为的X86服务器业务部门。2021年,华为将X86服务器业务剥离,成立超聚变,并落户河南郑州。(上证报)

28分钟前

谷歌重金押注中国AR企业,与XREAL深化战略合作

36氪获悉,CES 2026期间,谷歌与XREAL联合宣布达成深度长期战略合作。来自中国的AR创新企业XREAL是谷歌在AR眼镜领域的唯一硬件合作伙伴,已连续四年独占全球AR眼镜市场份额第一,双方首款合作产品Project Aura将于今年上市。另据知情人士透露,谷歌或将于年内完成对XREAL的投资,以此完善Android XR端到端生态圈,应对Meta、苹果的竞争挑战。

28分钟前

本页详细列出关于博奥生物的品牌信息,含品牌所属公司介绍,博奥生物所处行业的品牌地位及优势。
咨询